FTC to Halt Amgen’s Proposed $27.8 Billion Acquisition of Horizon Therapeutics – Insider Report by Reuters

The Federal Trade Commission (FTC) is reportedly planning to block Amgen’s proposed $27.8 billion acquisition of Horizon Therapeutics, citing antitrust concerns.

#FTC #Amgen #HorizonTherapeutics #antitrust #acquisition

Amgen’s Acquisition Bid for Horizon Therapeutics Under Scrutiny

According to an insider report by Reuters, the FTC will file a lawsuit to stop Amgen’s acquisition of Horizon Therapeutics. The report claims that the acquisition could substantially lessen competition in the U.S. market for treatments for chronic kidney disease, a condition that affects over 37 million Americans. The FTC is reportedly concerned that the acquisition could lead to higher prices and fewer treatment options for patients.

#Amgen #HorizonTherapeutics #competition #chronickidneydisease #FTC

Amgen and Horizon Therapeutics Respond to the FTC’s Plans

Both Amgen and Horizon Therapeutics have stated that they believe the acquisition is in the best interest of patients and that they plan to defend the deal in court. They have argued that the acquisition would combine two complementary businesses, providing more treatment options to patients and creating economies of scale that would lower costs.

#Amgen #HorizonTherapeutics #acquisition #patients #economiesofscale

What Does This Mean for Investors and Patients?

The FTC’s decision to block the acquisition could have far-reaching consequences for both investors and patients. If the acquisition is ultimately blocked, it could lead to a significant drop in Amgen’s stock price, as well as limit the company’s growth prospects. Patients, on the other hand, may face higher costs and fewer treatment options. The future direction of the case remains unclear, but it is clear that both Amgen and Horizon Therapeutics are prepared to fight for the deal.

#investors #patients #stockprice #growthprospects #Antitrustlawsuit

Summary

The FTC is reportedly planning to block Amgen’s proposed $27.8 billion acquisition of Horizon Therapeutics, citing antitrust concerns. The acquisition could substantially lessen competition in the U.S. market for treatments for chronic kidney disease, a condition that affects over 37 million Americans. Both Amgen and Horizon Therapeutics have stated that they believe the acquisition is in the best interest of patients and that they plan to defend the deal in court. If the acquisition is ultimately blocked, it could lead to a significant drop in Amgen’s stock price, as well as limit the company’s growth prospects. Patients may also face higher costs and fewer treatment options. #BUSINESS